ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...

ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...

ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...

ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...

ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...